{"id":70007,"date":"2026-07-15T12:12:54","date_gmt":"2026-07-15T04:12:54","guid":{"rendered":"https:\/\/flcube.com\/?p=70007"},"modified":"2026-07-15T12:12:55","modified_gmt":"2026-07-15T04:12:55","slug":"biogen-advances-diranersen-into-phase-3-development-following-positive-alzheimers-phase-2-data","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70007","title":{"rendered":"Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer&#8217;s Phase 2 Data"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Biogen Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>)<\/strong> presented <strong>positive Phase 2 CELIA study data<\/strong> for <strong>diranersen (BIIB080)<\/strong>, an <strong>investigational antisense oligonucleotide (ASO) therapy<\/strong>, in individuals with <strong>early Alzheimer&#8217;s disease<\/strong> at the <strong>Alzheimer&#8217;s Association International Conference (AAIC) 2026<\/strong>. Based on consistent evidence from Phase 1b and Phase 2 studies, Biogen plans to <strong>advance diranersen into confirmatory Phase 3 development<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-milestone\" class=\"wp-block-heading\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Name<\/strong><\/td><td>Phase 2 CELIA<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Early Alzheimer&#8217;s disease<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Individuals with early Alzheimer&#8217;s disease<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>ADAS-Cog13, MMSE, CDR-SB cognitive assessments<\/td><\/tr><tr><td><strong>Key Results<\/strong><\/td><td>42% slowing on ADAS-Cog13, 50% on MMSE, 26% on CDR-SB (60 mg dose)<\/td><\/tr><tr><td><strong>Next Phase<\/strong><\/td><td>Confirmatory Phase 3 development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Investigational antisense oligonucleotide (ASO) therapy (BIIB080)<\/li>\n\n\n\n<li><strong>Target:<\/strong> Microtubule-associated protein tau (MAPT) mRNA<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Reduces production of tau protein by targeting MAPT mRNA<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First ASO therapy demonstrating consistent cognitive benefit across multiple endpoints in early Alzheimer&#8217;s disease<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-2-celia-study\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase 2 CELIA Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>60 mg Dose Result<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>ADAS-Cog13<\/strong><\/td><td>42% slowing of clinical decline<\/td><td>Primary cognitive assessment tool for Alzheimer&#8217;s<\/td><\/tr><tr><td><strong>MMSE<\/strong><\/td><td>50% slowing of clinical decline<\/td><td>Standard screening measure for cognitive impairment<\/td><\/tr><tr><td><strong>CDR-SB<\/strong><\/td><td>26% slowing of clinical decline<\/td><td>Global measure of dementia severity<\/td><\/tr><tr><td><strong>Dose Response<\/strong><\/td><td>Efficacy demonstrated across all studied doses at 18 months<\/td><td>Consistent results across prespecified clinical endpoints<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The study demonstrated that diranersen&#8217;s 60 mg dose showed the strongest response, with statistically significant slowing of clinical decline across all major cognitive endpoints, representing a potentially meaningful clinical benefit for patients with early Alzheimer&#8217;s disease.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-therapeutic-landscape\" class=\"wp-block-heading\">Market Impact &amp; Therapeutic Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Alzheimer&#8217;s Disease Market:<\/strong> With limited disease-modifying options and significant unmet need, a tau-targeting therapy showing cognitive benefit represents a major therapeutic advance<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Unlike amyloid-focused therapies, diranersen targets tau pathology, which correlates more closely with cognitive decline in Alzheimer&#8217;s disease<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> Positions Biogen to potentially offer both amyloid and tau-targeting therapies, creating a comprehensive Alzheimer&#8217;s treatment portfolio<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding diranersen&#8217;s clinical development and regulatory pathway. Actual results may differ due to risks including Phase 3 trial outcomes, regulatory approvals, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[351,17,993],"class_list":["post-70007","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-biogen","tag-clinical-trial-results","tag-nasdaq-biib"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer&#039;s Phase 2 Data - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy, in individuals with early Alzheimer&#039;s disease at the Alzheimer&#039;s Association International Conference (AAIC) 2026. Based on consistent evidence from Phase 1b and Phase 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70007\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer&#039;s Phase 2 Data\" \/>\n<meta property=\"og:description\" content=\"Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy, in individuals with early Alzheimer&#039;s disease at the Alzheimer&#039;s Association International Conference (AAIC) 2026. Based on consistent evidence from Phase 1b and Phase 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70007\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T04:12:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-15T04:12:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70007#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70007\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer&#8217;s Phase 2 Data\",\"datePublished\":\"2026-07-15T04:12:54+00:00\",\"dateModified\":\"2026-07-15T04:12:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70007\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biogen\",\"Clinical trial results\",\"NASDAQ: BIIB\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70007#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70007\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70007\",\"name\":\"Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer's Phase 2 Data - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-15T04:12:54+00:00\",\"dateModified\":\"2026-07-15T04:12:55+00:00\",\"description\":\"Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy, in individuals with early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. Based on consistent evidence from Phase 1b and Phase 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70007#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70007\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70007#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer&#8217;s Phase 2 Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer's Phase 2 Data - Insight, China&#039;s Pharmaceutical Industry","description":"Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy, in individuals with early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. Based on consistent evidence from Phase 1b and Phase 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70007","og_locale":"en_US","og_type":"article","og_title":"Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer's Phase 2 Data","og_description":"Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy, in individuals with early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. Based on consistent evidence from Phase 1b and Phase 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.","og_url":"https:\/\/flcube.com\/?p=70007","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-15T04:12:54+00:00","article_modified_time":"2026-07-15T04:12:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70007#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70007"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer&#8217;s Phase 2 Data","datePublished":"2026-07-15T04:12:54+00:00","dateModified":"2026-07-15T04:12:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70007"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biogen","Clinical trial results","NASDAQ: BIIB"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70007#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70007","url":"https:\/\/flcube.com\/?p=70007","name":"Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer's Phase 2 Data - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-15T04:12:54+00:00","dateModified":"2026-07-15T04:12:55+00:00","description":"Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy, in individuals with early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. Based on consistent evidence from Phase 1b and Phase 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70007#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70007"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70007#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer&#8217;s Phase 2 Data"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70007"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70007\/revisions"}],"predecessor-version":[{"id":70009,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70007\/revisions\/70009"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}